Abstract:Objective To investigate the effects of early treatment of montelukast on the airway inflammation and remodeling in murine asthma model.Methods Twenty-four mice were divided into 3 groups(8 in each group) including group A[ovalbumin(OVA) sensitized/challenged mice],group B(saline sensitized/challenged mice),group C(OVA sensitized/challenged mice treated with montelukast in the early phase).Mice were sensitized on day1 and day14 by OVA and challenged from days 24 to 41 by OVA repeatedly to establish a murine model of asthma characterized by airway inflammation and airway remodeling.Monterlukast(6 mg/kg) were given from the day before OVA challenge in group C.The differential counts of inflammatory cells in bronchoaveolar lavage fluids(BALF),peripheral blood(PB) as well as eosinophils(EOS) count in bone marrow(BM) were calculated.Airway inflammation indices,EOS count,amount of collagen deposition around the bronchus,area of airway smooth muscle,the degree of mucus secretion in the lumens and depth of airway smooth muscle(ASM) in bronchus of different grade were studied by HE,PAS and Masson′s staining.The supernatant collected from BALF,PB,and BM were assayed for IL-5.The BALF were also assayed for INF-γ(levels).Results In repeatedly OVA-challenged mice (group A),EOS counts in BALF,PB and BM [(45.09±4.08) ×10~4/mL,(2.41±0.31)×10~5/mL,(1.51±0.18)×10~6/femur] were increased significantly when compared with group B[(0.08±0.03)×10~4/mL,(0.62±0.09)×10~4/mL,(0.63±0.09)×10~6/femur,all P<0.01],respectively.The IL-5 levels in BALF and PB in group A increased significantly compared with group B [BALF:((57.86±)2.72) pg/mL vs (18.68±2.46) pg/mL,P<0.01;PB:(18.76±0.84) pg/mL vs(12.11±0.51) pg/mL,P<0.01] while IFN-γ in BALF decreased significantly [(36.55±1.71) pg/mL vs(64.53±5.72) pg/mL,P<0.01].EOS counts around bronchus were increased in group A [(912.12±65.97)/mm~2] when compared with group B[(8.79±2.61)/mm~2,P<0.01].Goblet cells hyperplasia [(51.12±3.50)% vs((1.92±)0.67)%,P<0.01 ]and mucus hypersecretion [score:(3.48±0.12) vs(0.17±0.08),P<0.01],airway smooth muscle hypertrophy [(25.99±0.89)μm~2/μm vs(13.06±0.60) μm~2/μm,(P<)0.01],enhanced collagen deposition of reticular basement membrane(RBM) [(29.69±2.02) μm~2/μm vs(5.56±0.35)μm~2/μm,P<0.01] were more significant in group A than those in group B.Treated with Montelukast early resulted in decreased EOS counts [(6.25±0.79)×10~4/mL in BALF,(0.71±0.11)×10~5/mL in PB and(0.77±0.10)×10~6/femur in BM],declined IL-5 levels [(25.96±1.79)pg/mL in BALF,(13.14±0.55) pg/mL in serum] and increased IFN-γ levels [(52.70±2.15)pg/mL in BALF].Montelukast also attenuated the remodeling procedure in the airway described above.Conclusions Prolonged allergen exposure could induce airway structural changes characteristic of excessive collagen deposition.Montelukast,an anti-(inflammatory) agent,has inhibitory activity on airway remodeling.

Effects of Montelukast on Muc5ac Expression in Lung of Asthmatic Mice

Study on Cysteinyl Leukotriene Receptor Antagonist Depressing Acute Asthma Airway Inflammation

Montelukast modulates lung CysLT1 receptor expression and eosinophilic inflammation in asthmatic mice

Effect of montelukast on the secretion of mucus protein in human bronchial epithelial cells

Effect of montelukast on the apoptosis of eosinophil in bronchoalveloar lavage fluid

Effects of montelukast on airway inflammation and remodeling in murine model of asthma

Effect of Leukotriene Receptor Antagonist on IL-10 Experession in the Lungs of Asthmatic Mice

Montelukast, a Leukotriene Receptor Antagonist, Modulates Lung CysLT1

Changes of Eosinophils in Bronchoalveolar Lavage Fluid of Asthma in Children and the Modulation Effect of Montelukast

Effects of Montelukast on Mrna Expression of MUC2 and MUC5B in Human Nasal Epithelial Cells

The Effects of the Leukotriene Receptor Antagonist on MUC5AC Gene Expression in Cultured Human Nasal Epithelial Cells

Effect of Leukotriene Receptor Antagonist on HMGB1 Expression in the Lungs of Asthmatic Mice

Effect of inhaled glucocorticoid and leukotriene receptor on IL-6 expression in the lungs of asthmatic mice

A Study on the Effects of Cysteinyl Leukotriene Receptor Antagonist and Dexamethasone on the Transcription Level of Arginase - I in Asthmatic Mouse Models

Enhanced Local Foxp3 Expression in Lung Tissue Attenuates Airway Inflammation in A Mouse Model of Asthma

Effects of Glucocorticoid and Cysteinyl Leukotriene 1 Receptor Antagonist on CD(34+) Hematopoietic Cells in Bone Marrow of Asthmatic Mice.

Effect of leukotrienes receptor antagonist on the expressional levels of matrix metalloproteinase- 9 and its inhibitor TIMP- 1 in rats with asthma

A study on the effects of cysteinyl leukotriene receptor antagonist and corticosteroid on the expression levels of matrix metalloproteinase-2 in asthmatic mouse models

Effects of Ozone Repeated Short Exposures on the Airway/lung Inflammation, Airway Hyperresponsiveness and Mucus Production in a Mouse Model of Ovalbumin-Induced Asthma.

The effects of neutralizing anti-murine interleukin-17A monoclonal antibody on ozone-induced inflammation and glucocorticoids insensitivity in a murine model of asthma

The contribution of the WNT pathway to the therapeutic effects of montelukast in experimental murine airway inflammation induced by ovalbumin and lipopolysaccharide